GlassScriptPhysician profile
Huma Hasnain Kennedy
NPI 1619175718
$1,344.33
in general payments reported to CMS, 2019-2025
12 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $107 · 2021: $217 · 2022: $131 · 2023: $128 · 2024: $293 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518 · Education: $63.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.85 |
| Education | $63.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $149.98 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $146.20 | 2024 | Terlivaz |
| Fresenius USA Marketing, INC. | $125.00 | 2023 | Velphoro |
| Amgen INC. | $122.10 | 2025 | |
| Alexion Pharmaceuticals, INC. | $121.90 | 2019 | |
| Glaxosmithkline, LLC. | $121.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $116.70 | 2021-2022 | |
| Gilead Sciences, INC. | $116.57 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $109.74 | 2022 | |
| Edwards Lifesciences Corporation | $106.54 | 2020 | |
| Baxter Healthcare | $70.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.70 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.